Teva Rasagiline Filing Set For Second Half 2003; Firm Touts Metabolic Profile
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Teva will likely emphasize the once-daily dosing and metabolic profile of its MAO-B inhibitor rasagiline to distinguish the Parkinson’s disease therapy from selegiline.
You may also be interested in...
Valeant Responds To Zelapar Approvable Letter, Plans For Mid-2005 Launch
Valeant responds to Zelapar “approvable” letter for Parkinson’s disease; “complete response” includes two safety studies, as requested in FDA’s 2003 approvable letter for the MAO-B inhibitor. Selegiline safety concerns include drug interactions, hypertension due to “cheese effect”
Valeant Responds To Zelapar Approvable Letter, Plans For Mid-2005 Launch
Valeant responds to Zelapar “approvable” letter for Parkinson’s disease; “complete response” includes two safety studies, as requested in FDA’s 2003 approvable letter for the MAO-B inhibitor. Selegiline safety concerns include drug interactions, hypertension due to “cheese effect”
Teva/Eisai rasagiline deal
Eisai will co-promote Teva's MAO-B inhibitor rasagiline in North America for Parkinson's disease under a deal that also calls for global co-development for Alzheimer's disease. Teva recently announced successful completion of its Phase III Parkinson's program, with an FDA filing set for second half 2003 (1Pharmaceutical Approvals Monthly May 1, p. 14)...